{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:30:11Z","timestamp":1780471811695,"version":"3.54.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Rituximab is a monoclonal antibody inducing depletion of B lymphocytes and presently approved for the treatment of non-Hodgkin's lymphoma and rheumatoid arthritis. Here is the first report of the use of this drug in a case of Cogan's syndrome (CS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case Presentation<\/jats:title>\n            <jats:p>a 25-year-old Italian woman was referred with conjunctival hyperaemia, interstitial keratitis, moderate bilateral sensorineural hearing loss accompanied by tinnitus, dizziness, nausea and vertigo, poorly responsive to oral and topical steroidal therapy. Diagnosis of typical CS was made. The administration of a combined immunosuppressive treatment resolved ocular inflammation, dizziness, nausea, and vertigo but gave little results in controlling progressive hearing loss. A noticeable improvement in hearing function was documented by pure tone audiometry after infusion of Rituximab.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>in CS, hearing function is often the most difficult parameter to control with therapy. A positive effect of Rituximab on was observed in our case. The drug also allowed to significantly reduce the number of adjuvant immunosuppressive medications.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1750-1172-5-18","type":"journal-article","created":{"date-parts":[[2010,6,16]],"date-time":"2010-06-16T20:32:40Z","timestamp":1276720360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Rituximab ameliorated severe hearing loss in Cogan's syndrome: a case report"],"prefix":"10.1186","volume":"5","author":[{"given":"Jelka G","family":"Orsoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierangela","family":"Rubino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Zavota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Bacciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,16]]},"reference":[{"key":"181_CR1","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","volume":"98","author":"J Golay","year":"2001","unstructured":"Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, Rambaldi A, Introna M: CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. 2001, 98: 3383-3389. 10.1182\/blood.V98.12.3383.","journal-title":"Blood"},{"key":"181_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/08916930601119377","volume":"40","author":"C Bonaguri","year":"2007","unstructured":"Bonaguri C, Orsoni JG, Zavota L, Monica C, Russo A, Pellistri I, Rubino P, Goivannelli L, Manzotti F, Piazza F: Anti-68 kDa antibodies in autoimmune sensorineural hearing loss: are these autoantibodies really a diagnostic tool?. Autoimmunity. 2007, 40: 73-78. 10.1080\/08916930601119377.","journal-title":"Autoimmunity"},{"key":"181_CR3","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1755-3768.2008.01256.x","volume":"87","author":"JG Orsoni","year":"2009","unstructured":"Orsoni JG, Zavota L, Mora P, Rubino P, Manzotti F, Pellistri I: Discontinuous drug combination therapy in autoimmune ocular disorders. Acta Ophthalmol. 2009, 87: 340-345. 10.1111\/j.1755-3768.2008.01256.x.","journal-title":"Acta Ophthalmol"},{"key":"181_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1177\/000348948609500213","volume":"95","author":"GJ Peeters","year":"1986","unstructured":"Peeters GJ, Cremers CW, Pinckers AJ, Hoefnagel WH: Atypical Cogan's syndrome: an autoimmune disease?. Ann Otol Rhinol Laryngol. 1986, 95: 173-175.","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"181_CR5","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00296-009-0945-0","volume":"29","author":"G Murphy","year":"2009","unstructured":"Murphy G, Sullivan MO, Shanahan F, Harney S, Molloy M: Cogan's syndrome: present and future directions. Reumathol Int. 2009, 29: 1117-1121. 10.1007\/s00296-009-0945-0.","journal-title":"Reumathol Int"},{"key":"181_CR6","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.rdc.2007.07.015","volume":"33","author":"M Mazlumzadeh","year":"2007","unstructured":"Mazlumzadeh M, Matteson EL: Cogan's syndrome: an audiovestibular, ocular, and systemic autoimmune disease. Rheum Dis Clin North Am. 2007, 33: 855-874. 10.1016\/j.rdc.2007.07.015.","journal-title":"Rheum Dis Clin North Am"},{"key":"181_CR7","volume-title":"Int J Pediatr Otorhinolaringol","author":"C Hautefort","year":"2009","unstructured":"Hautefort C, Loundon N, Montchilova M, Marlin S, Garabedian EN, Ulinski T: Mycophenolate mofetil as a treatment of steroid dependent Cogan's syndrome in childhood. Int J Pediatr Otorhinolaringol. 2009,"},{"key":"181_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/art.21179","volume":"53","author":"EL Matteson","year":"2005","unstructured":"Matteson EL, Choi HK, Poe DS, Wise C, Lowe VJ, McDonald TJ, Rahman MU: Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study. Arthritis Rheum. 2005, 53: 337-342. 10.1002\/art.21179.","journal-title":"Arthritis Rheum"},{"key":"181_CR9","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00296-006-0252-y","volume":"27","author":"M Fricker","year":"2007","unstructured":"Fricker M, Baumann F, Wermelinger F, Villiger PM, Helbling A: A novel therapeutic option in Cogan diseases? TNF-a blockers. Rheumatol Int. 2007, 27: 493-495. 10.1007\/s00296-006-0252-y.","journal-title":"Rheumatol Int"},{"key":"181_CR10","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.3899\/jrheum.080203","volume":"35","author":"R Ghadban","year":"2008","unstructured":"Ghadban R, Couret M, Zenone T: Efficacy of Infliximab in Cogan's Syndrome. J Rheumatol. 2008, 35: 2456-2458. 10.3899\/jrheum.080203.","journal-title":"J Rheumatol"},{"key":"181_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/j.1749-6632.2009.04639.x","volume":"1173","author":"C Alc\u00e2ntara","year":"2009","unstructured":"Alc\u00e2ntara C, Gomes MJ, Ferreira C: Rituximab therapy in primary Sj\u00f6gren's syndrome. Ann N Y Acad Sci. 2009, 1173: 701-705. 10.1111\/j.1749-6632.2009.04639.x.","journal-title":"Ann N Y Acad Sci"},{"key":"181_CR12","volume-title":"Rheumatol Int","author":"KK D\u00f8nvik","year":"2009","unstructured":"D\u00f8nvik KK, Omdal R: Churg-Strauss syndrome successfully treated with rituximab. Rheumatol Int. 2009,"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1750-1172-5-18.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T04:22:41Z","timestamp":1630470161000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/1750-1172-5-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,16]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["181"],"URL":"https:\/\/doi.org\/10.1186\/1750-1172-5-18","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,16]]},"assertion":[{"value":"11 February 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"18"}}